The Mechanism of Action of IL-2 in the Tumor Microenvironment and its Application in Melanoma
DOI:
https://doi.org/10.54097/fr761521Keywords:
IL-2; tumor microenvironment; melanoma.Abstract
Cancer, the leading cause of death worldwide, causes a large number of deaths each year and this number is expected to increase with the aging of the population. In this context, it has become particularly important to study and understand in depth the role of cytokines in the tumor microenvironment (TME). Cytokines, particularly interleukin 2 (IL-2), are key regulators of the human immune system and play a pivotal role in the TME.IL-2 plays a crucial role in regulating immune cell proliferation, differentiation, and function, thereby influencing the body's immune response to tumors. However, signaling by IL-2 and its receptor (IL-2R) may be dysregulated in TME, and this dysregulation has profound effects on tumor growth and anti-tumor immune responses. Specifically, dysregulated IL-2 signaling may promote tumor growth and spread while suppressing the body's immune response to the tumor. Translated with DeepL.com (free version) This review summarizes the mechanism of IL-2 and its signal pathway in the TME according to the current popular clinical research object. Based on the side effects of IL-2 during clinical application (such as short half-life and toxicity of high doses of IL-2), this article introduces a new strategy for developing IL-2-cytokine immunotherapy in melanoma treatment. Together, this work aims to provide readers with a timely view of the field of engineered IL-2, highlighting a more promising avenue for future research and development.
Downloads
References
Skrombolas D., et al. 2 Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Review of Clinical Immunology, 2014, 10(2): 207–217.
Tanaka A., & Sakaguchi S. 3 Regulatory T cells in cancer immunotherapy. Cell Research, 2017, 27(1): 109–118.
Jared E Lopes, et al. 7 ALKS 4230: A novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. Journal for ImmunoTherapy of Cancer, 2020, 8(1): e000673.
Li Z., et al. 8 Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer. OncoImmunology, 2017: 6(3), e1290038.
Uricoli B., et al. 9 Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy. Advanced Healthcare Materials, 2021, 10(15): 2002214.
Kumar P., et al. 10 the cure from within? A review of the microbiome and diet in melanoma. Cancer and Metastasis Reviews, 2020, 41(2): 261–280.
Boyman O., & Sprent, J. 6 The role of interleukin-2 during homeostasis and activation of the immune system. Nature Reviews Immunology, 2012, 12(3): 180–190.
Silver A.B., et al. 13 an engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2. Cell Reports Medicine, 2023, 4(11): 101289.
Létourneau S., et al. 4 IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107(5), 2171–2176.
Levin A.M., et al. 15 exploiting a natural conformational switch to engineer an interleukin-2 “superkine”. Nature, 2012, 484(7395): 529–533.
Arenas-Ramirez N., et al. 16 Improved cancer immunotherapy by a CD25-embody conferring selectivity to human interleukin-2. Science Translational Medicine, 2016, 8(367): 367ra166-367ra166.
Charych D. H., et al. 11 NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models. Clinical Cancer Research, 2016, 22(3): 680–690.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







